No Data
No Data
Needham Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $84
Buy Rating for Crispr Therapeutics AG: Strong Pipeline, Strategic Partnerships, and Financial Stability Drive Confidence
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones
Can 2025 J.P. Morgan Healthcare Conference Spark Biotech M&A?
Gene Editing Stocks Drop as Intellia Announces Layoffs
OptionMetrics and CRSP Announce Partnership Giving Academic Researchers Increased Integration of U.S. Equities and Options Data in Research
No Data
Warren Buffed : no i share losses,daily basis too
102631395 : Me too
ppspirit : Thank you for your honest sharing. Thank you for making me feel I am normal and it is normal to not have good days. As long as these companies are still earning, I think we are safe.
Far Out : I am also a big loser, just recently lost more than half of my positions in ionq and qbet after Jansun Huang made a comment about Quountom computer.
EscapeGoat OG OP : yes guys we all know it's hard and painful when we lose big time. but also take that as a learning lesson specially when it comes to diversification and position sizing. in the early days of my trading adventures I would routinely get wiped out and suffered morally for days or weeks to come. now a days I only invest about 3 to 5 percent of my portfolio and if I lost the whole position is no big deal because I know I still have other chances of coming back, granted my earnings are not as big as I would like but are consistent and my account continues to grow, all the best to all and may your future hold fruitful rewards.